Published online before print May 28, 2007, doi: 10.1161/CIRCULATIONAHA.106.671222
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:2801-2813.)
© 2007 American Heart Association, Inc.
Cardiovascular Surgery |
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
From the Center for the Evaluative Clinical Sciences (J.R.B., G.T.O.) and Departments of Medicine and of Community and Family Medicine (G.T.O.), Dartmouth Medical School, Hanover, NH, and Michigan Surgical Collaboration for Outcomes Research and Evaluation, University of Michigan, Ann Arbor (N.J.O.B.).
Correspondence to Jeremiah R. Brown, PhD, Clinical Research Section, Rubin 505, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH 03756. E-mail Jeremiah.Brown{at}Dartmouth.edu
Received October 19, 2006; accepted March 26, 2007.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Since the 1980s, antifibrinolytic therapies have assisted surgical teams in reducing the amount of blood loss. To date, however, serious questions remain regarding the safety and effectiveness of these agents.
Methods and Results— We conducted a meta-analysis to compare aprotinin, 
-aminocaproic acid, and tranexamic acid with placebo and head to head on 8 clinical outcomes from 138 trials. Published randomized controlled trial data were collected from OVID/PubMed. Outcomes included total blood loss, transfusion of packed red blood cells, reexploration, mortality, stroke, myocardial infarction, dialysis-dependent renal failure, and renal dysfunction (0.5-mg/dL increase in creatinine from baseline). All agents were effective in significantly reducing blood loss by 226 to 348 mL and the proportion of patients transfused with packed red blood cells over placebo. Only high-dose aprotinin reduced the rate of reexploration (relative risk, 0.49; 95% CI, 0.33 to 0.73). There were no significant risks or benefits for any agent for mortality, stroke, myocardial infarction, or renal failure. However, high-dose aprotinin significantly increased the risk of renal dysfunction (relative risk, 1.47; 95% CI, 1.12 to 1.94), 12.9% versus 8.4%. Compared head to head, high-dose aprotinin demonstrated significant reduction in total blood loss over -aminocaproic acid (–184 mL; 95% CI, –256 to –112) and tranexamic acid (–195 mL; 95% CI, –286 to –105). There were no significant differences among any agent when compared head to head on other outcomes.
Conclusions— All antifibrinolytic agents were effective in reducing blood loss and transfusion. There were no significant risks or benefits for mortality, stroke, myocardial infarction, or renal failure. However, high-dose aprotinin was associated with a statistically significant increased risk of renal dysfunction.
Key Words: aminocaproic acids • aprotinin • meta-analysis • surgery • tranexamic acid
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Intraoperative bleeding and postoperative bleeding are frequent and often serious complications of cardiac surgery. Two thirds of patients having coronary artery bypass surgery are transfused with packed red blood cells (pRBCs). Cardiac surgery patients receive
20% of all pRBCs used in the United States.1 Blood transfusion benefits patients, but it is not without risk. Chelemer et al2 showed that each unit of pRBCs was associated with an increase in the incidence of bacterial infections. Speiss3 described the typical unit of pRBCs: the low pH, high potassium level, and limited ability to deliver oxygen to tissue. Others suggested that less transfusion may be equally effective4 and that there may be long-term adverse effects of blood transfusion.5
Editorial p 2790
Clinical Perspective p 2813
Three drugs used to decrease blood loss and the need for transfusion are in clinical use. -Aminocaproic acid (Amicar, Xanodyne Pharmaceuticals, Inc, Newport, Ky) inhibits fibrinolysis by the inhibition of plasminogen inhibitors and, to a lesser degree, through antiplasmin activity. Tranexamic acid (Cyklokapron, Pharmacia & Upjohn Co, Piscataway, NJ) is similar in action to -aminocaproic acid but is 10 times more potent. Aprotinin is a natural serine protease inhibitor (Tasylol, Bayer Pharmaceuticals Corp, West Haven, Conn) that affects multiple mediators, resulting in the attenuation of inflammatory responses, fibrinolysis, and thrombin generation.
These antifibrinolytic agents have been studied in hundreds of randomized trials, yet questions remain. An observational study by Mangano et al6,7 found that aprotinin was associated with increased risks of adverse cardiovascular, cerebrovascular, and renal outcomes. In a recent letter to the editor of the New England Journal of Medicine, we reported the results of a meta-analysis of the renal outcomes of aprotinin versus placebo.8 Subsequently, we extended this meta-analysis to include -aminocaproic acid and tranexamic acid. We summarized the effects of these agents compared with placebo and in head-to-head comparisons. The metrics included bleeding volume, transfusion rate, and adverse events, including mortality, stroke, myocardial infarction, and renal dysfunction (insufficiency and dialysis-dependent failure).
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Selection
We conducted a meta-analysis of randomized controlled trials including adult coronary artery bypass (CABG), isolated valve, or combined CABG/valve surgery. Both primary operations and reoperations were included in this analysis. OVID/Medline was used to identify published randomized controlled trials from 1985 through July 2006. Key words used to search included trasylol or aprotinin, aminocaproic acid or amicar, tranexamic acid, cardiac surgery or thoracic surgery, coronary artery bypass, or valve. The search yielded 242 published human randomized controlled trials. The search was further limited to the English language (226) and adults (185). Among the 185 studies remaining, 38 did not report outcomes of interest, and 9 were excluded for pump-only fibrinolytic therapy, leaving 138 trials with outcomes of interest to this meta-analysis (Figure 1).9–146
|
We abstracted data from the trials on 8 outcomes, including bleeding (intraoperative and postoperative blood loss was recorded in milliliters); the proportion of patients transfused with pRBCs; the proportion of patients returning to the operating room for reexploration; adverse events, including mortality, stroke, and myocardial infarction; and renal complications stratified by dialysis-dependent renal failure and renal dysfunction (0.5-mg/dL increase in creatinine). We defined renal failure as new onset of dialysis. There was 1 exception to this rule: Dialysis-dependent renal failure was not reported, but a 
2.0-mg/dL increase in creatinine was reported, which we defined as a renal failure and occurred in 1 study. Renal dysfunction was defined as a 0.5-mg/dL increase in creatinine.
We followed the appropriate methods for conducting a meta-analysis as stipulated in the Consolidated Standards of Reporting Trials (CONSORT) statement.147 Two independent reviewers selected trials for information outcomes and recorded data on spreadsheets. Jadad criteria were assessed and tabulated with study characteristics (see the Table in the online Data Supplement).148 Outcomes were stratified by Jadad score and were determined not to influence the results. Funnel plots were generated to evaluate possible publication bias. Patterns of bias were observed for high- and low-dose aprotinin with regard to total blood loss and the proportion of patients transfused with pRBCs. Patterns of bias also were observed for aminocaproic acid and tranexamic acid for the proportion of patients transfused with pRBCs. None of the other funnel plots by agent and outcome indicated evidence of publication bias.
To control for the dosing effect of aprotinin, we stratified our analysis by high- and low-dose aprotinin (as suggested by the manufacturer). High-dose (also referred to as full-dose) aprotinin consisted of a 2 million kallikrein-inhibiting units (KIU) IV loading dose, 2 million KIU pump-priming dose, and 0.5 million KIU IV/h maintenance dose. Low-dose (also referred to as half-dose) aprotinin consisted of a 1 million KIU IV loading dose, 1 million KIU pump-priming dose, and 0.25 million KIU IV/h maintenance dose. Cardiopulmonary bypass pump-only aprotinin was not included in our analysis because there were insufficient data (8 studies) to report outcomes of interest.
-Aminocaproic acid dosing varied from trial to trial but was consistent within each trial. We stratified our analysis by dividing the doses into high and low strata. We discovered that there was no significantly different effect between the high- and low-dosing categories for -aminocaproic acid. Therefore, we report the summary effect of all dosing of -aminocaproic acid.
Tranexamic acid dosing varied from trial to trial. After stratification analysis into 2 groups (high or low dose), we discovered that there was no significant difference in the effect of high-dose versus low-dose tranexamic acid. We report the summary effects for tranexamic acid for all dosing together.
There were 22 published trials reporting on "head-to-head" comparisons, ie, each agent compared with a competing agent. We compared aprotinin with tranexamic acid (15 studies), aprotinin with -aminocaproic acid (9 studies), and -aminocaproic acid with tranexamic acid (5 studies). All head-to-head comparisons involving aprotinin used high-dose aprotinin.
Statistical Analysis
All outcome comparisons and treatment effects were calculated with the Cochrane Collaborative software, RevMan 4.2.8. Effect modification was assessed by the Mantel-Haenszel test of homogeneity across subcategories of procedure type (CABG, CABG/valve, and valve) and for high and low dosing for -aminocaproic acid and tranexamic acid. In addition, we calculated the I2 to evaluate the percentage of heterogeneity among all the trials incorporated into the summary estimate.149 To control for heterogeneity, we used random-effects modeling. The weighted mean difference (WMD) and 95% CIs were calculated for continuous data (total blood loss in milliliters). For all dichotomous data (proportion of patients transfused with pRBCs, return to operating room/reexploration, stroke, mortality, myocardial infarction, renal failure, and renal dysfunction), relative risk (RR) and 95% CIs were calculated for each independent study and for the summary statistic. If any single cell (either in treatment or control) had no events, the software automatically added 0.5 to maintain its contribution in the analysis. Any study reporting no events in both the treatment and control groups was not included in the summary statistic calculation. The analysis was divided into 2 parts. First, each agent was compared with placebo. Second, a head-to-head analysis was done to compare each agent with a competing agent. Methods for the calculation of the above statistics have been reported previously.150,151
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Selection
There were 138 randomized controlled trials that reported outcomes of interest to this meta-analysis: total blood loss, proportion of patients transfused with pRBCs, return to operating room/reexploration, stroke, mortality, myocardial infarction, and renal failure or dysfunction complications. For placebo-controlled studies, there were 78 high-dose and 32 low-dose aprotinin studies, 18
-aminocaproic acid studies, and 31 tranexamic acid studies. For head-to-head comparative studies, there were 15 aprotinin versus tranexamic acid, 9 aprotinin versus -aminocaproic acid, and 5 -aminocaproic acid versus tranexamic acid studies. We found no evidence for effect modification by procedure type for all agents or for dosing effects for -aminocaproic acid or tranexamic acid.
Placebo Comparisons
Bleeding
Comparisons of antifibrinolytic agents with placebo by outcomes and effect estimates are reported in Table 1. Patients receiving either high- or low-dose aprotinin, -aminocaproic acid, or tranexamic acid had considerably less total blood loss compared with placebo-controlled patients (Figure 2). Patients receiving high-dose aprotinin on average lost 348 mL (95% CI, –416 to –281; P<0.001) less blood than did their counterparts receiving placebo. Low-dose aprotinin (6 studies, 515 patients) reduced total blood loss by 226 mL on average (95% CI, –277 to –175 mL; P<0.001). -Aminocaproic acid resulted in 240 mL less blood loss (95% CI, –341 to –140 mL; P<0.001), and tranexamic acid resulted in 285 mL less blood loss (95% CI, –394 to –175 mL; P<0.001).
|
|
All antifibrinolytic agents were significantly effective at reducing the proportion of patients requiring transfusion of pRBCs compared with placebo-controlled patients (Figure 3). Patients treated with high-dose aprotinin had a 40% reduced rate of transfusion compared with placebo-controlled patients (RR, 0.60; 95% CI, 0.53 to 0.67; P<0.001). A 24% reduced rate of transfusion (RR, 0.76; 95% CI, 0.66 to 0.86; P<0.001) was observed for patients treated with low-dose aprotinin. -Aminocaproic acid reduced the rate of transfusion by 37% (RR, 0.63; 95% CI, 0.44 to 0.90; P=0.010). Tranexamic acid reduced the rate of transfusion by 25% (RR, 0.75; 95% CI, 0.60 to 0.92; P=0.007).
|
High-dose aprotinin significantly reduced the rate of reexploration by 51% (RR, 0.49; 95% CI, 0.33 to 0.73; P<0.001) compared with placebo. Low-dose aprotinin did not significantly reduce the rate for reexploration compared with placebo-treated patients (RR, 0.69; 95% CI, 0.41 to 1.18; P=0.18). Neither -aminocaproic acid (RR, 0.51; 95% CI, 0.15 to 1.82; P=0.30) nor tranexamic acid (RR, 0.70; 95% CI, 0.44 to 1.11; P=0.12) significantly reduced the rate of reexploration compared with placebo-controlled patients. However, all agents demonstrated a trend toward reduced rates of reexploration with similar summary effect measures.
Adverse Outcomes
Adverse outcomes, including mortality, stroke, and myocardial infarction, are reported in Figure 4 and Table 1. Forty-three studies reported adverse outcomes for high-dose aprotinin; 16 studies reported adverse outcomes for low-dose aprotinin. There were 8 studies for -aminocaproic acid and 18 studies for tranexamic acid.
|
There were no statistically significant risks or benefits for any of these antifibrinolytic agents with regard to mortality, stroke, or myocardial infarction (Table 1 and Figure 4). High-dose aprotinin did not significantly protect patients from mortality or place patients at risk of death (RR, 0.89; 95% CI, 0.65 to 1.21; P=0.46). There was no mortality risk or benefit for low-dose aprotinin (RR, 1.37; 95% CI, 0.72 to 2.59; P=0.34), -aminocaproic acid (RR, 1.82; 95% CI, 0.55 to 5.98; P=0.3240), or tranexamic acid (RR, 0.67; 95% CI, 0.33 to 1.37; P=0.28). There was no significant risk or benefit for stoke as observed for high-dose aprotinin (RR, 0.67; 95% CI, 0.30 to 1.47; P=0.32), low-dose aprotinin (RR, 0.47; 95% CI, 0.09 to 2.36; P=0.36), -aminocaproic acid (RR, 0.60; 95% CI, 0.13 to 2.81; P=0.52), or tranexamic acid (RR, 1.31; 95% CI, 0.59 to 2.93; P=0.51). There was no significant risk or protection against myocardial infarction from any of the antifibrinolytic agents: high-dose aprotinin (RR, 1.10; 95% CI, 0.83 to 1.45; P=0.52), low-dose aprotinin (RR, 0.94; 95% CI, 0.58 to 1.54; P=0.82), -aminocaproic acid (RR, 1.14; 95% CI, 0.50 to 2.60; P=0.76), or tranexamic acid (RR, 0.94; 95% CI, 0.51 to 1.74; P=0.85). Antifibrinolytic therapies do not place patients at increased risk of mortality, stroke, or myocardial infarction, nor do they demonstrate a significant protective effect.
Renal Complications
No agent demonstrated a significant increased risk of dialysis-dependent renal failure (Figure 5): high-dose aprotinin (RR, 1.09; 95% CI, 0.68 to 1.77; P=0.71), low-dose aprotinin (RR, 1.86; 95% CI, 0.07 to 49.26; P=0.71), and tranexamic acid (RR, 1.43; 95% CI, 0.30 to 6.85; P=0.66). There were no renal outcomes reported for -aminocaproic acid. However, as previously shown,8 high-dose aprotinin resulted in a 47% increased risk of renal dysfunction (RR, 1.47; 95% CI, 1.12, 1.94; P=0.006), defined as a 0.5-mg/dL increase in creatinine from baseline. No increase in the risk of renal dysfunction was observed for low-dose aprotinin (RR, 1.01; 95% CI, 0.69 to 1.49; P=0.96). There were no trials reporting renal dysfunction with -aminocaproic acid to include in this analysis. There was no statistically significant risk of renal dysfunction observed with tranexamic acid (RR, 2.02; 95% CI, 0.73 to 5.60; P=0.18), although a nonsignificant trend toward renal dysfunction was observed.
|
Stratified Analysis
We investigated the possibility that results stratified by the type of procedure (eg, CABG, CABG/valve, valve only) could affect the results. We compared each agent with placebo for the proportion of patients transfused with pRBCs. High-dose aprotinin stratified by procedures resulted in similar summary estimates: RR, 0.60, 95% CI, 0.53 to 0.67 (all procedures); RR, 0.62, 95% CI, 0.55 to 0.70 (CABG); RR, 0.44, 95% CI, 0.34 to 0.59 (CABG/valve); and RR, 0.41, 95% CI, 0.21 to 0.80 (valve). Low-dose aprotinin estimates were similar across procedure type: RR, 0.76, 95% CI, 0.66 to 0.86 (all); RR, 0.75, 95% CI, 0.64 to 0.88 (CABG); RR, 0.87, 95% CI, 0.78 to 0.97 (CABG/valve); and RR, 0.89, 95% CI, 0.58 to 1.37 (valve). -Aminocaproic acid resulted in similar estimates across procedures: RR, 0.63, 95% CI, 0.44 to 0.90 (all); RR, 0.60, 95% CI, 0.39 to 0.91 (CABG); and RR, 0.77, 95% CI, 0.35 to 1.70 (CABG/valve), with no estimates for valve surgery. Tranexamic acid stratified by procedure type showed similar results with the exception of valve surgery: RR, 0.75, 95% CI, 0.60 to 0.92 (all); RR, 0.75, 95% CI, 0.57 to 0.98 (CABG); RR, 0.69, 95% CI, 0.48 to 0.98 (CABG/valve); and RR, 1.40, 95% CI, 1.17 to 1.69 (valve). When stratified by the type of procedure, the estimates were similar. Tranexamic acid had a significantly increased risk for the proportion of patients transfused with pRBCs among valve-only procedures; however, this was not observed for total blood loss by procedure type.
Head-to-Head Comparisons
Bleeding
Head-to-head comparisons of antifibrinolytic agents are reported in Table 2. High-dose aprotinin resulted in 195 mL less total blood loss compared with tranexamic acid (95% CI, –286 to –105 mL; P<0.001). High-dose aprotinin resulted in 184 mL less total blood loss compared with -aminocaproic acid (95% CI, –256 to –112 mL; P<0.001; Figure 6). -Aminocaproic acid and tranexamic acid did not differ significantly in total blood loss (WMD, –64 mL; 95% CI, –214 to 85 mL; P=0.40).
|
|
High-dose aprotinin did not significantly reduce the rate of transfusion compared with tranexamic acid (RR, 0.81; 95% CI, 0.60 to 1.09; P=0.17) or -aminocaproic acid (RR, 0.93; 95% CI, 0.71 to 1.22; P=0.60). There was no significant difference in the rate of transfusion when -aminocaproic acid was compared with tranexamic acid (RR, 0.81; 95% CI, 0.49 to 1.34; P=0.41). High-dose aprotinin did not significantly reduce the rate of reexploration compared with tranexamic acid (RR, 0.90; 95% CI, 0.50 to 1.63; P=0.73) or -aminocaproic acid (RR, 1.04; 95% CI, 0.40 to 2.72; P=0.94). There was no statistically significant difference in the rate of reexploration when -aminocaproic acid was compared with tranexamic acid (RR, 0.72; 95% CI, 0.20 to 2.56; P=0.62).
Adverse Outcomes
There were no statistically significant differences for high-dose aprotinin over tranexamic acid or -aminocaproic acid in reducing mortality, stroke, or myocardial infarction (Table 2 and Figure 7) when antifibrinolytic agents were compared head to head. High-dose aprotinin compared with tranexamic acid was not significantly different with regard to mortality (RR, 1.29; 95% CI, 0.63 to 2.65; P=0.49). Likewise, mortality, when high-dose aprotinin is compared with -aminocaproic acid, was not significantly different (RR, 0.97; 95% CI, 0.06 to 15.22; P=0.98). -Aminocaproic acid did not significantly differ from tranexamic acid in mortality (RR, 3.85; 95% CI, 0.43 to 34.28; P=0.23). Compared with tranexamic acid, high-dose aprotinin was not significantly different with regard to stroke (RR, 1.52; 95% CI, 0.58 to 4.03; P=0.39) or myocardial infarction (RR, 0.89; 95% CI, 0.52 to 1.50; P=0.65). Compared with -aminocaproic acid, high-dose aprotinin did not significantly differ in regard to stroke (RR, 3.96; 95% CI, 0.44 to 35.27; P=0.22) or myocardial infarction (RR, 1.20; 95% CI, 0.30 to 4.89; P=0.79). -Aminocaproic acid did not significantly differ from tranexamic acid in terms of stroke (RR, 0.33; 95% CI, 0.03 to 3.10; P=0.33) or myocardial infarction (RR, 1.00; 95% CI, 0.29 to 3.46; P=1.00).
|
Overall, there was no significant difference among antifibrinolytic agents with regard to mortality, stroke, or myocardial infarction. There is no demonstrated risk or benefit of 1 agent over another.
Renal Complications
Published studies reporting on head-to-head comparisons for renal failure and renal dysfunction outcomes were rare. One study that compared high-dose aprotinin with tranexamic acid reported renal failure outcomes. Two studies of the same comparison reported renal dysfunction outcomes (Table 2). There was no significant difference in renal failure between high-dose aprotinin and tranexamic acid (RR, 1.01; 95% CI, 0.36 to 2.85; P=0.99).34 Renal dysfunction was not significantly different between high-dose aprotinin and tranexamic acid (RR, 1.07; 95% CI, 0.55 to 2.10; P=0.84).34,152 One head-to-head study compared low-dose aprotinin with -aminocaproic acid in 100 patients and reported no renal dysfunction events.153 No studies that reported renal outcomes compared -aminocaproic acid with tranexamic acid.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this meta-analysis of published randomized clinical trials of antifibrinolytic agents, we found that aprotinin,
-aminocaproic acid, and tranexamic acid all reduce total blood loss and rates of transfusion in cardiac surgery compared with placebo. Although only high-dose aprotinin significantly reduced reexploration rates, there was a similarly protective effect observed for all of the agents. There were no significant effects of the drugs on mortality, stroke, or myocardial infarction. High-dose aprotinin, however, was associated with a significant increase in rates of renal dysfunction (12.9% versus 8.4%).8 The present study adds 5 years and nearly doubles the number of studies included in previously reported meta-analyses on this topic. Our analysis included all cardiac surgery procedures, in contrast to the Sedrakyan et al154 study, and analyzed the aprotinin trials stratified by dose, in contrast to the Cochrane Collaborative study.150 Our results do not confirm the findings of Sedrakyan et al of a significant reduction in the risk of stroke among coronary bypass patients receiving aprotinin in either the combined results or those stratified according to procedure.
In contrast to the recently published observational study by Mangano et al,6,7 aprotinin did not significantly increase risks of mortality, stroke, myocardial infarction, or renal failure requiring dialysis in our meta-analysis of published trials. However, as we previously reported,8 our results confirm the findings of Mangano et al6 and Karkouti et al155 of an increased risk of renal dysfunction among patients receiving aprotinin. We believe that these discrepancies between our findings and those of Mangano et al lie in the difference between observational and experimental study designs. The major limitation of observational cohort studies for evaluating treatment efficacy is confounding by indication, also known as treatment selection bias. Although standard statistical methods can be used to control for measured differences in prognosis between the treatment groups, confounding by unmeasured factors cannot be removed. Randomization deals effectively with both measured and unmeasured confounding; therefore, randomized trials are regarded as the most rigorous design for studying the effectiveness of alternative treatments. The downside of randomized trials is that they are conducted under such highly controlled, ideal circumstances that their results may not be applicable to usual clinical conditions. The Mangano et al study included samples drawn from consecutive cardiac surgery patients and found that those treated with antifibrinolytics were at higher risk for adverse outcomes than the untreated control patients. Patients included in the randomized trials summarized in this meta-analysis consisted of low-risk, elective patients whose antifibrinolytic treatments were randomly allocated.
The definition of renal dysfunction as a 0.5-mg/dL elevation in postoperative serum creatinine is widely accepted. It is the definition consistently used and reported in the trials and other cardiac surgery studies. Renal dysfunction defined in this way has been shown to increase the risk of 30-day mortality with cardiac surgery by 18-fold, demonstrating its usefulness as a metric in clinical trials.156 With recent studies showing an increase in renal dysfunction in patients treated with aprotinin, some have raised the possibility that elevations in serum creatinine among aprotinin-treated patients may be artificial because of the accumulation of the drug in the proximal renal tubules, which does not occur among the lysine analogues. The Food and Drug Administration advisory panel reviewing the new evidence was not swayed by this argument, however, and has recommended labeling changes to alert physicians to the risks of kidney damage with the use of aprotinin.157
Our findings should be interpreted in light of limitations that are common to all meta-analyses. In meta-analysis, heterogeneity is the term used to describe inconsistencies in outcomes between studies. One potential source of heterogeneity in this meta-analysis is the combination of trials that include patients undergoing different cardiac procedures or treated with different antifibrinolytic doses. To address these issues, we performed stratified analyses to assess the extent to which our results varied according to procedure type and aprotinin dose. Finding no important interactions, we present only the combined results but have included the raw data in an appendix (online Data Supplement), allowing interested readers to make a more detailed examination of the results.
Another limitation of meta-analysis is variability in the quality of the individual trials. In our study, 36 of the published trials included in this meta-analysis violated the intention-to-treat principle by excluding patients from the analysis after they had been randomized. Twenty-three trials excluded patients from the analysis for the occurrence of reexploration. Eighteen of those trials reported the study arm from which the excluded patients (for reexploration) were derived. In our analysis, we reconciled these patients back to their originally assigned arms and included them in this meta-analysis on the intention-to-treat basis. However, 5 of 23 trials excluding patients for reexploration did not report which study arm the excluded patients were assigned; therefore, we were unable to reconcile those patients to their original arm.140,158–161 In the case of high-dose aprotinin, 2 of these 5 studies reported reexploration as an outcome.159,160 Both studies reported reexploration events for the placebo group but none for the aprotinin group despite the fact that some patients were excluded from the analysis for reexploration. In these 2 studies, there was concern about reporting bias. For this reason, we removed these studies from our reexploration analysis. Once removed, the summary effect (RR) changed from 0.47 (95% CI, 0.32 to 0.69; P<0.001) to 0.49 (95% CI, 0.33 to 0.73; P<0.001) and did not change the results.
One reason to perform a meta-analysis is that numerous small trials will be performed to evaluate the effectiveness of a treatment. By combining studies, we increase the power to evaluate rare adverse effects. We conducted a post hoc analysis to assess the power of this meta-analysis to evaluate some of the rare adverse outcomes reported and found it lacking. For example, the power of our study ranged from 0.05 for dialysis-dependent renal failure to 0.35 for stroke. This study would have required >80 000 patients in each treatment group to detect a significant difference in rates of dialysis-dependent renal failure. Renal dysfunction was the only adverse outcome for which we had sufficient power (0.85) to detect a significant difference between treatment groups.
In summary, we have conducted an updated meta-analysis, confirming previous findings of meta-analyses that captured only published clinical trials through 1998151 and 2001.150 We extended these findings by expanding the review of trials through July 2006 and by evaluating the dosing effect of aprotinin on blood loss and adverse outcomes. Our findings demonstrate that both high- and low-dose aprotinin, -aminocaproic acid, and tranexamic acid reduce total perioperative blood loss during cardiac surgery, reducing the need for transfusion. However, high-dose aprotinin results in less total blood loss than either of the competing antifibrinolytic agents and results in lower rates of reexploration. There was no difference among these agents in risks of mortality, stroke, myocardial infarction, or renal failure, but high-dose aprotinin significantly increased the rates of renal dysfunction.
|
Acknowledgments |
|---|
Disclosures
None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Stover EP, Siegel LC, Parks R, Levin J, Body SC, Maddi R, D’Ambra MN, Mangano DT, Spiess BD. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Anesthesiology. 1998; 88: 327–333.[CrossRef][Medline] [Order article via Infotrieve]
2. Chelemer SB, Prato BS, Cox PM, O’Connor GT, Morton JR. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg. 2002; 73: 138–142.
3. Speiss BD. Transfusion and outcome in heart surgery. Ann Thorac Surg. 2002; 74: 986–987.
4. Johnson RG, Thurer RL, Kruskall MS, Sirois C, Gervino EV, Critchlow J, Weintraub RM. Comparison of 2 transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg. 1992; 104: 307–314.[Abstract]
5. Busch ORC, Hop WCJ, Vanpapendrecht MAWH, Marquet RL, Jeekel J. Blood-transfusions and prognosis in colorectal-cancer. N Engl J Med. 1993; 328: 1372–1376.
6. Mangano DT, Tudor IC, Dietzel C; for the Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006; 354: 353–365.
7. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007; 297: 471–479.
8. Brown JR, Birkmeyer NJO, O’Connor GT. Aprotinin in cardiac surgery. N Engl J Med. 2006; 354: 1953–1957.
9. Alajmo F, Calamai G, Perna AM, Melissano G, Pretelli P, Palmarini MF, Carbonetto F, Noferi D, Boddi V, Palminiello A, Vaccari M. High-dose aprotinin: hemostatic effects in open-heart operations. Ann Thorac Surg. 1989; 48: 536–539.[Abstract]
10. Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman B, Nadel A. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 1998; 116: 716–730.
11. Alvarez JM, Jackson LR, Chatwin C, Smolich JJ. Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg. 2001; 122: 457–463.
12. Alvarez JM, Quiney NF, McMillan D, Joscelyne K, Connelly T, Brady P, Deal C, Wilson R. The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. J Cardiothorac Vasc Anesth. 1995; 9: 29–33.[CrossRef][Medline] [Order article via Infotrieve]
13. Andreasen JJ, Nielsen C. Prophylactic tranexamic acid in elective, primary coronary artery bypass surgery using cardiopulmonary bypass. Eur J Cardiothorac Surg. 2004; 26: 311–317.
14. Armellin G, Casella S, Guzzinati S, Pasini L, Marcassa A, Giron G. Tranexamic acid in aortic valve replacement. J Cardiothorac Vasc Anesth. 2001; 15: 331–335.[CrossRef][Medline] [Order article via Infotrieve]
15. Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC, Taylor KM. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2000; 69: 1192–1197.
16. Baele PL, Ruiz-Gomez J, Londot C, Sauvage M, Van Dyck MJ, Robert A. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesthesiol Belg. 1992; 43: 103–112.[Medline] [Order article via Infotrieve]
17. Bailey CR, Kelleher AA, Wielogorski AK. Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery. Br J Surg. 1994; 81: 969–973.[Medline] [Order article via Infotrieve]
18. Bailey CR, Wielogorski AK. Randomised placebo controlled double blind study of two low dose aprotinin regimens in cardiac surgery. Br Heart J. 1994; 71: 349–353.
19. Basora M, Gomar C, Escolar G, Pacheco M, Fita G, Rodriguez E, Ordinas A. Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin. J Cardiothorac Vasc Anesth. 1999; 13: 382–387.[CrossRef][Medline] [Order article via Infotrieve]
20. Bennett-Guerrero E, Sorohan JG, Gurevich ML, Kazanjian PE, Levy RR, Barbera AV, White WD, Slaughter TF, Sladen RN, Smith PK, Newman MF. Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. Anesthesiology. 1997; 87: 1373–1380.[CrossRef][Medline] [Order article via Infotrieve]
21. Bernet F, Carrel T, Marbet G, Skarvan K, Stulz P. Reduction of blood loss and transfusion requirements after coronary artery bypass grafting: similar efficacy of tranexamic acid and aprotinin in aspirin-treated patients. J Card Surg. 1999; 14: 92–97.[Medline] [Order article via Infotrieve]
22. Bidstrup B. Aprotinin for bleeding after cardiopulmonary bypass. Lancet. 1990; 335: 1535–1536.[Medline] [Order article via Infotrieve]
23. Bidstrup BP, Hunt BJ, Sheikh S, Parratt RN, Bidstrup JM, Sapsford RN. Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting. Ann Thorac Surg. 2000; 69: 541–547.
24. Bidstrup BP, Royston D, Taylor KM, Sapsford RN. Reduction in blood-loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 1989; 97: 364–372.[Abstract]
25. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg. 1993; 105: 147–152.[Abstract]
26. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaardhansen P. Effects of high-dose aprotinin on blood-loss, platelet-function, fibrinolysis, complement, and renal-function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991; 101: 958–967.[Abstract]
27. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaardhansen P. Comparison of the effects of aprotinin and tranexamic acid on blood-loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994; 108: 1083–1091.
28. Boldt J, Schindler E, Knothe C, Hammermann H, Stertmann WA, Hempelmann G. Does aprotinin influence endothelial-associated coagulation in cardiac surgery? J Cardiothorac Vasc Anesth. 1994; 8: 527–531.[CrossRef][Medline] [Order article via Infotrieve]
29. Brown RS, Thwaites BK, Mongan PD. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial. Anesth Analg. 1997; 85: 963–970.[Abstract]
30. Casas JI, Zuazujausoro I, Mateo J, Oliver A, Litvan H, Munizdiaz E, Aris A, Caralps JM, Fontcuberta J. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass: a double-blind placebo-controlled study. J Thorac Cardiovasc Surg. 1995; 110: 1107–1117.
31. Casati V, Bellotti F, Gerli C, Franco A, Oppizzi M, Cossolini M, Calori G, Benussi S, Alfieri O, Torri G. Tranexamic acid administration after cardiac surgery: a prospective, randomized, double-blind, placebo-controlled study. Anesthesiology. 2001; 94: 8–14.[CrossRef][Medline] [Order article via Infotrieve]
32. Casati V, Della Valle P, Benussi S, Franco A, Gerli C, Baili P, Alfieri O, D’Angelo A. Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: comparison between on-pump and off-pump techniques. J Thorac Cardiovasc Surg. 2004; 128: 83–91.
33. Casati V, Gerli C, Franco A, Torri G, D’Angelo A, Benussi S, Alfieri O. Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study. Ann Thorac Surg. 2001; 72: 470–475.
34. Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, Gerli C, Cossolini M, Torri G, Calori G, Benussi S, Alfieri O. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg. 2000; 120: 520–527.
35. Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Alfieri O. Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery. Ann Thorac Surg. 1999; 68: 2252–2256.
36. Cicek S, Demirkilic U, Kuralay E, Ozal E, Tatar H. Postoperative aprotinin: effect on blood loss and transfusion requirements in cardiac operations. Ann Thorac Surg. 1996; 61: 1372–1376.
37. Cicek S, Demirkilic U, Ozal E, Kuralay E, Bingol H, Tatar H, Ozturk OY. Postoperative use of aprotinin in cardiac operations: an alternative to its prophylactic use. J Thorac Cardiovasc Surg. 1996; 112: 1462–1467.
38. Coffey A, Pittmam J, Halbrook H, Fehrenbacher J, Beckman D, Hormuth D. The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial. Am Surg. 1995; 61: 566–568.[Medline] [Order article via Infotrieve]
39. Cosgrove DM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR, Stewart RW, Mccarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg. 1992; 54: 1031–1038.[Abstract]
40. D’Ambra MN, Akins CW, Blackstone EH, Bonney SL, Cohn LH, Cosgrove DM, Levy JH, Lynch KE, Maddi R. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg. 1996; 112: 1081–1089.
41. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: a randomized, prospective, double-blind study. J Thorac Cardiovasc Surg. 1994; 108: 99–106.
42. De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U, Schiavello R, Possati GF. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000; 119: 575–580.
43. Defraigne JO, Pincemail J, Larbuisson R, Blaffart F, Limet R. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg. 2000; 69: 1084–1091.
44. Delrossi AJ, Cernaianu AC, Botros S, Lemole GM, Moore R. Prophylactic treatment of postperfusion bleeding using EACA. Chest. 1989; 96: 27–30.[CrossRef][Medline] [Order article via Infotrieve]
45. Dernek S, Sevin B, Aslan R, Kaklikkaya I, Atalay C, Kural T. Effects of aprotinin on plasma levels of neutrophil elastase and postoperative blood loss in cardiac surgery. Cardiovasc Surg. 1996; 4: 515–519.[CrossRef][Medline] [Order article via Infotrieve]
46. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years’ experience in 1,784 patients. J Cardiothorac Vasc Anesth. 1992; 6: 324–327.[CrossRef][Medline] [Order article via Infotrieve]
47. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery: a double-blind, placebo-controlled study. Anesthesiology. 1995; 83: 679–689.[CrossRef][Medline] [Order article via Infotrieve]
48. Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay A, Sebening F, Richter JA. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology. 1990; 73: 1119–1126.[Medline] [Order article via Infotrieve]
49. Diprose P, Herbertson MJ, O’Shaughnessy D, Deakin CD, Gill RS. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. Br J Anaesth. 2005; 94: 271–278.
50. Dryden PJ, O’Connor JP, Jamieson WR, Reid I, Ansley D, Sadeghi H, Burr LH, Munro AI, Merrick PM. Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery. Can J Anaesth. 1997; 44: 934–941.[Medline] [Order article via Infotrieve]
51. Englberger L, Kipfer B, Berdat PA, Nydegger UE, Carrel TP. Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response? Ann Thorac Surg. 2002; 73: 1897–1904.
52. Englberger L, Markart P, Eckstein FS, Immer FF, Berdat PA, Carrel TP. Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery. Eur J Cardiothorac Surg. 2002; 22: 545–551.
53. Fauli A, Gomar C, Campistol JM, Alvarez L, Manig AM, Matute P. Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass. Eur J Anaesthesiol. 2005; 22: 666–671.[CrossRef][Medline] [Order article via Infotrieve]
54. Feindt P, Seyfert U, Volkmer I, Huwer H, Kalweit G, Gams E. Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery? Eur J Cardiothorac Surg. 1994; 8: 308–313.[Abstract]
55. Feindt PR, Walcher S, Volkmer I, Keller HE, Straub U, Huwer H, Seyfert UT, Petzold T, Gams E. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg. 1995; 60: 1076–1080.
56. Forestier F, Belisle S, Robitaille D, Martineau R, Perrault LP, Hardy JF. Low-dose aprotinin is ineffective to treat excessive bleeding after cardiopulmonary bypass. Ann Thorac Surg. 2000; 69: 452–456.
57. Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin: preliminary results. Thorac Cardiovasc Surg. 1989; 37: 89–91.[Medline] [Order article via Infotrieve]
58. Golanski R, Golanski J, Chizynski K, Iwaszkiewicz A, Zaslonka J, Pietrucha T, Chrul S, Watala C. Low doses of aprotinin in aortocoronary bypass surgery: advantages and disadvantages. Med Sci Monit. 2000; 6: 722–728.[Medline] [Order article via Infotrieve]
59. Gott JP, Cooper WA, Schmidt FE Jr, Brown WM 3rd, Wright CE, Merlino JD, Fortenberry JD, Clark WS, Guyton RA. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg. 1998; 66: 747–753.
60. Green D, Sanders J, Eiken M, Wong CA, Frederiksen J, Joob A, Palmer A, Trowbridge A, Woodruff B, Moerch M. Recombinant aprotinin in coronary artery bypass graft operations. J Thorac Cardiovasc Surg. 1995; 110: 963–970.
61. Greilich PE, Brouse CF, Rinder CS, Smith BR, Sandoval BA, Rinder HM, Eberhart RC, Jessen ME. Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology. 2004; 100: 225–233.[CrossRef][Medline] [Order article via Infotrieve]
62. Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg. 2003; 126: 1498–1503.
63. Greilich PE, Okada K, Latham P, Kumar RR, Jessen ME. Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid. Circulation. 2001; 104 (suppl): I-265–I-269.[Medline] [Order article via Infotrieve]
64. Harder MP, Eijsman L, Roozendaal KJ, Vanoeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood-loss in membrane-oxygenator cardiopulmonary bypass. Ann Thorac Surg. 1991; 51: 936–941.[Abstract]
65. Hardy JF, Belisle S, Dupont C, Harel F, Robitaille D, Roy M, Gagnon L. Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization. Ann Thorac Surg. 1998; 65: 371–376.
66. Hardy JF, Desroches J, Belisle S, Perrault J, Carrier M, Robitaille D. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth. 1993; 40: 625–631.[Medline] [Order article via Infotrieve]
67. Harig F, Hohenstein B, von der Emde J, Weyand M. Modulating IL-6 and IL-10 levels by pharmacologic strategies and the impact of different extracorporeal circulation parameters during cardiac surgery. Shock. 2001; 16 (suppl 1): 33–38.[Medline] [Order article via Infotrieve]
68. Harmon DC, Ghori KG, Eustace NP, O’Callaghan SJ, O’Donnell AP, Shorten GD. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can J Anaesth. 2004; 51: 1002–1009.[Medline] [Order article via Infotrieve]
69. Hashimoto K, Onoguchi K, Sasaki T, Hachiya T, Takakura H, Nagahori R, Takeuchi S. Strategy for balancing anticoagulation and hemostasis in aortocoronary bypass surgery: blood conservation and graft patency. Jpn Circ J. 1999; 63: 165–169.[CrossRef][Medline] [Order article via Infotrieve]
70. Havel M, Teufelsbauer H, Knobl P, Dalmatiner R, Jaksch P, Zwolfer W, Muller M, Vukovich T. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg. 1991; 101: 968–972.[Abstract]
71. Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K, Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1997; 114: 261–269.
72. Horrow JC, Hlavacek J, Strong MD, Collier W, Brodsky I, Goldman SM, Goel IP. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg. 1990; 99: 70–74.[Abstract]
73. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation. 1991; 84: 2063–2070.
74. Jamieson WR, Dryden PJ, O’Connor JP, Sadeghi H, Ansley DM, Merrick PM. Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery. Circulation. 1997; 96 (suppl): II-96–II-100.
75. Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg. 1994; 8: 651–656.[Abstract]
76. Karski J, Djaiani G, Carroll J, Iwanochko M, Seneviratne P, Liu P, Kucharczyk W, Fedorko L, David T, Cheng D. Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: a prospective randomized controlled clinical trial. J Thorac Cardiovasc Surg. 2005; 130: 309–314.
77. Karski JM, Teasdale SJ, Norman P, Carroll J, Vankessel K, Wong P, Glynn MFX. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid: double-blind, randomized clinical trial. J Thorac Cardiovasc Surg. 1995; 110: 835–842.
78. Katoh J, Tsuchiya K, Sato W, Nakajima M, Iida Y. Additional postbypass administration of tranexamic acid reduces blood loss after cardiac operations. J Thorac Cardiovasc Surg. 1997; 113: 802–804.
79. Katsaros D, Petricevic M, Snow NJ, Woodhall DD, Van Bergen R. Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. Ann Thorac Surg. 1996; 61: 1131–1135.
80. Kawasuji M, Ueyama K, Sakakibara N, Tedoriya T, Matsunaga Y, Misaki T, Watanabe Y. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann Thorac Surg. 1993; 55: 1205–1209.[Abstract]
81. Kikura M, Levy JH, Tanaka KA, Ramsay JG. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg. 2006; 202: 216–222.[CrossRef][Medline] [Order article via Infotrieve]
82. Klein M, Keith PR, Dauben HP, Schulte HD, Beckmann H, Mayer G, Elert O, Gams E. Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with aspirin. Eur J Cardiothorac Surg. 1998; 14: 360–366.[CrossRef][Medline] [Order article via Infotrieve]
83. Kluger R, Olive DJ, Stewart AB, Blyth CM. Epsilon-aminocaproic acid in coronary artery bypass graft surgery: preincision or postheparin? Anesthesiology. 2003; 99: 1263–1269.[CrossRef][Medline] [Order article via Infotrieve]
84. Koster A, Huebler S, Merkle F, Hentschel T, Grundel M, Krabatsch T, Tambeur L, Praus M, Habazettl H, Kuebler WM, Kuppe H. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response. Anesth Analg. 2004; 98: 285–290.
85. Kreisler KR, Vance RA, Cruzzavala J, Mahnken JD. Heparin-bonded cardiopulmonary bypass circuits reduce the rate of red blood cell transfusion during elective coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2005; 19: 608–611.[CrossRef][Medline] [Order article via Infotrieve]
86. Kuepper F, Dangas G, Mueller-Chorus A, Kulka PM, Zenz M, Wiebalck A. Fibrinolytic activity and bleeding after cardiac surgery with cardiopulmonary bypass and low-dose aprotinin therapy. Blood Coagul Fibrinolysis. 2003; 14: 147–153.[CrossRef][Medline] [Order article via Infotrieve]
87. Kuitunen A, Hiippala S, Vahtera E, Rasi V, Salmenpera M. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery. Acta Anaesthesiol Scand. 2005; 49: 1272–1279.[CrossRef][Medline] [Order article via Infotrieve]
88. Kunt AS, Darcin OT, Aydin S, Demir D, Selli C, Andac MH. Mini-dose pump-prime aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after coronary artery bypass surgery. J Thromb Thrombolysis. 2005; 19: 197–200.[CrossRef][Medline] [Order article via Infotrieve]
89. Landymore RW, Murphy JT, Lummis H, Carter C. The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations. Eur J Cardiothorac Surg. 1997; 11: 798–800.[Abstract]
90. Lass M, Simic O, Ostermeyer J. Re-graft patency and clinical efficacy of aprotinin in elective bypass surgery. Cardiovasc Surg. 1997; 5: 604–607.[CrossRef][Medline] [Order article via Infotrieve]
91. Lass M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A. Aprotinin in elective primary bypass surgery: graft patency and clinical efficacy. Eur J Cardiothorac Surg. 1995; 9: 206–210.[Abstract]
92. Laub GW, Riebman JB, Chen C, Adkins MS, Anderson WA, Fernandez J, McGrath LB. The impact of aprotinin on coronary artery bypass graft patency. Chest. 1994; 106: 1370–1375.[CrossRef][Medline] [Order article via Infotrieve]
93. Lemmer JH Jr, Dilling EW, Morton JR, Rich JB, Robicsek F, Bricker DL, Hantler CB, Copeland JG 3rd, Ochsner JL, Daily PO, Whitten CW, Noon GP, Maddi R. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg. 1996; 62: 1659–1667.
94. Lemmer JH Jr, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency: a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg. 1994; 107: 543–551.
95. Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995; 92: 2236–2244.
96. Li S, Ji H, Lin J, Lenehan E, Ji B, Liu J, Long C, Crane TA. Combination of acute preoperative plateletpheresis, cell salvage, and aprotinin minimizes blood loss and requirement during cardiac surgery. J Extra Corpor Technol. 2005; 37: 9–14.[Medline] [Order article via Infotrieve]
97. Liu B, Belboul A, Radberg G, Tengborn L, Dernevik L, Roberts D, William-Olsson G. Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg. 1993; 27: 149–155.[Medline] [Order article via Infotrieve]
98. Liu YC, Tsai TP. The effect of coagulation protection with combination of epsilon aminocaproic acid and plasma saver in open-heart surgery. Acta Anaesthesiol Sin. 1998; 36: 149–154.[Medline] [Order article via Infotrieve]
99. Luo J, Huang Y, Lan H. Effect of aprotinin on the red cell immunity in cardiopulmonary bypass. J Tongji Med Univ. 1998; 18: 97–100.[Medline] [Order article via Infotrieve]
100. Maineri P, Covaia G, Realini M, Caccia G, Ucussich E, Luraschi M, Crosta A, Foresti B, Chiaranda M. Postoperative bleeding after coronary revascularization: comparison between tranexamic acid and epsilon-aminocaproic acid. Minerva Cardioangiol. 2000; 48: 155–160.[Medline] [Order article via Infotrieve]
101. Menichetti A, Tritapepe L, Ruvolo G, Speziale G, Cogliati A, Di Giovanni C, Pacilli M, Criniti A. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg (Torino). 1996; 37: 401–407.[Medline] [Order article via Infotrieve]
102. Mercieri M, Mercieri A, Tritapepe L, Ruggeri M, Arcioni R, Repetto M, Bottari B, Menichetti A. High-dose aprotinin with gentamicin-vancomycin antibiotic prophylaxis increases blood concentrations of creatinine and cystatin C in patients undergoing coronary artery bypass grafting. Br J Anaesth. 1999; 82: 531–536.
103. Mohr R, Goor DA, Lusky A, Lavee J Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction: a scanning electron microscope study. Circulation. 1992; 86 (suppl): II-405–II-409.[Medline] [Order article via Infotrieve]
104. Mongan PD, Brown RS, Thwaites BK. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization. Anesth Analg. 1998; 87: 258–265.
105. Moran SV, Lema G, Medel J, Irarrazaval MJ, Zalaquett R, Garayar B, Flaskamp R. Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery. Perfusion. 2000; 15: 105–110.
106. Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, Novick RJ. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 1994; 107: 554–561.
107. Nakashima A, Matsuzaki K, Fukumura F, Hisahara M, Kanegae Y, Fukae K, Miyamoto K, Nishida T, Tokunaga S, Tominaga R. Tranexamic acid reduces blood loss after cardiopulmonary bypass. ASAIO J. 1993; 39: M185–M189.[CrossRef][Medline] [Order article via Infotrieve]
108. Nuttall GA, Oliver WC, Ereth MH, Santrach PJ, Bryant SC, Orszulak TA, Schaff HV. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology. 2000; 92: 674–682.[CrossRef][Medline] [Order article via Infotrieve]
109. Olivencia-Yurvati AH, Wallace WE, Wallace N, Dimitrijevich D, Knust JK, Haas L, Raven PB. Intraoperative treatment strategy to reduce the incidence of postcardiopulmonary bypass atrial fibrillation. Perfusion. 2002; 17 (suppl): 35–39.
110. Orchard MA, Goodchild CS, Prentice CR, Davies JA, Benoit SE, Creighton-Kemsford LJ, Gaffney PJ, Michelson AD. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol. 1993; 85: 533–541.[Medline] [Order article via Infotrieve]
111. Ozal E, Kuralay E, Bingol H, Cingoz F, Ceylan S, Tatar H. Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis? J Thorac Cardiovasc Surg. 2002; 123: 539–543.
112. Penta de Peppo A, Pierri MD, Scafuri A, De Paulis R, Colantuono G, Caprara E, Tomai F, Chiariello L. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery: prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J. 1995; 22: 231–236.[Medline] [Order article via Infotrieve]
113. Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O. Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Anesth Analg. 2003; 96: 923–928.
114. Pugh SC, Wielogorski AK. A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 1995; 9: 240–244.[CrossRef][Medline] [Order article via Infotrieve]
115. Ray MJ, Brown KF, Burrows CA, O’Brien MF. Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass. Ann Thorac Surg. 1999; 68: 940–945.
116. Ray MJ, Hales M, Marsh N. Epsilon-aminocaproic acid promotes the release of alpha2-antiplasmin during and after cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2001; 12: 129–135.[CrossRef][Medline] [Order article via Infotrieve]
117. Ray MJ, Hales MM, Brown L, O’Brien MF, Stafford EG. Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit. Ann Thorac Surg. 2001; 72: 521–526.
118. Ray MJ, Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost. 1997; 78: 1021–1026.[Medline] [Order article via Infotrieve]
119. Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation. 1994; 90: 921–927.
120. Rodrigus IE, Vermeyen KM, De Hert SG, Amsel BJ, Walter PJ. Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study. Perfusion. 1996; 11: 313–318.[Medline] [Order article via Infotrieve]
121. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood-transfusion after repeat open-heart-surgery. Lancet. 1987; 2: 1289–1291.[CrossRef][Medline] [Order article via Infotrieve]
122. Santamaria A, Mateo J, Muniz-Diaz E, Oliver A, Murillo J, Litvan H, Souto JC, Fontcuberta J. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. Haematologica. 2000; 85: 381–385.[Medline] [Order article via Infotrieve]
123. Schweizer A, Hohn L, Morel DR, Kalangos A, Licker M. Aprotinin does not impair renal haemodynamics and function after cardiac surgery. Br J Anaesth. 2000; 84: 16–22.
124. Shinfeld A, Zippel D, Lavee J, Lusky A, Shinar E, Savion N, Mohr R. Aprotinin improves hemostasis after cardiopulmonary bypass better than single-donor platelet concentrate. Ann Thorac Surg. 1995; 59: 872–876.
125. Shore-Lesserson L, Reich DL, Vela-Cantos F, Ammar T, Ergin MA. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Anesth Analg. 1996; 83: 18–26.[Abstract]
126. Slaughter TF, Faghih F, Greenberg CS, Leslie JB, Sladen RN. The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg. 1997; 85: 1221–1226.[Abstract]
127. Speekenbrink RG, Bertina RM, Espana F, Wildevuur CR, Eijsman L. Activation of the protein C system during cardiopulmonary bypass with and without aprotinin. Ann Thorac Surg. 1998; 66: 1998–2002.
128. Speekenbrink RG, Vonk AB, Wildevuur CR, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg. 1995; 59: 438–442.
129. Speekenbrink RG, Wildevuur CR, Sturk A, Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg. 1996; 112: 523–530.
130. Stammers A, Huffman S, Alonso A, Fristoe L, Hill G, Casebeer D, Diego R, Song Z. The antiinflammatory effects of aprotinin in patients undergoing cardiac surgery with cardiopulmonary bypass. J Extra Corpor Technol. 1997; 29: 114–122.
131. Swart MJ, Gordon PC, Hayse-Gregson PB, Dyer RA, Swanepoel AL, Buckels NJ, Schall R, Odell JA. High-dose aprotinin in cardiac surgery: a prospective, randomized study. Anaesth Intensive Care. 1994; 22: 529–533.[Medline] [Order article via Infotrieve]
132. Taggart DP, Djapardy V, Naik M, Davies A. A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting. J Thorac Cardiovasc Surg. 2003; 126: 1087–1094.
133. Tassani P, Augustin N, Barankay A, Braun SL, Zaccaria F, Richter JA. High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2000; 14: 682–686.[CrossRef][Medline] [Order article via Infotrieve]
134. Tempe DK, Banerjee A, Virmani S, Mehta N, Panwar S, Tomar AS, Ghambeer DK, Nigam M. Comparison of the effects of a cell saver and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing valve surgery. J Cardiothorac Vasc Anesth. 2001; 15: 326–330.[CrossRef][Medline] [Order article via Infotrieve]
135. Troianos CA, Sypula RW, Lucas DM, D’Amico F, Mathie TB, Desai M, Pasqual RT, Pellegrini RV, Newfeld ML. The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting. Anesthesiology. 1999; 91: 430–435.[CrossRef][Medline] [Order article via Infotrieve]
136. Turkoz A, Cigli A, But K, Sezgin N, Turkoz R, Gulcan O, Ersoy MO. The effects of aprotinin and steroids on generation of cytokines during coronary artery surgery. J Cardiothorac Vasc Anesth. 2001; 15: 603–610.[CrossRef][Medline] [Order article via Infotrieve]
137. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation. 2005; 112 (suppl): I-276–I-280.[CrossRef][Medline] [Order article via Infotrieve]
138. Vander Salm TJ, Ansell JE, Okike ON, Marsicano TH, Lew R, Stephenson WP, Rooney K. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg. 1988; 95: 538–540.[Abstract]
139. VanderSalm TJ, Kaur S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, Leone L, Li JM, Valeri CR, Michelson AD. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg. 1996; 112: 1098–1107.
140. Vanek T, Jares M, Fajt R, Straka Z, Jirasek K, Kolesar M, Brucek P, Maly M. Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). Eur J Cardiothorac Surg. 2005; 28: 563–568.
141. Vedrinne C, Girard C, Jegaden O, Blanc P, Bouvier H, Ffrench P, Mikaeloff P, Estanove S. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth. 1992; 6: 319–323.[CrossRef][Medline] [Order article via Infotrieve]
142. Wei M, Kuukasjarv P, Laurikka J, Pehkonen E, Kaukinen S, Honkonen EL, Moilanen E, Tarkka M. Cardioprotective effect of pump prime aprotinin in coronary artery bypass grafting. Cardiovasc Drugs Ther. 2002; 16: 37–42.[CrossRef][Medline] [Order article via Infotrieve]
143. Wei M, Kuukasjarvi P, Laurikka J, Pehkonen E, Kaukinen S, Laine S, Tarkka M. Pump prime aprotinin fails to limit proinflammatory cytokine release after coronary artery bypass surgery. Scand Cardiovasc J. 2001; 35: 50–54.[CrossRef][Medline] [Order article via Infotrieve]
144. Wei MX, Jian KT, Guo ZP, Li PJ, Han JG, Cai Z, Tarkka M. Effects of half-dose aprotinin in off-pump coronary artery bypass grafting. World J Surg. 2006; 30: 1108–1114.[CrossRef][Medline] [Order article via Infotrieve]
145. Wendel HP, Heller W, Michel J, Mayer G, Ochsenfahrt C, Graeter U, Schulze J, Hoffmeister HM, Hoffmeister HE. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg. 1995; 109: 1164–1172.
146. Wong BI, McLean RF, Fremes SE, Deemar KA, Harrington EM, Christakis GT, Goldman BS. Aprotinin and tranexamic acid for high transfusion risk cardiac surgery. Ann Thorac Surg. 2000; 69: 808–816.
147. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: Quality of Reporting of Meta-Analyses. Lancet. 1999; 354: 1896–1900.[CrossRef][Medline] [Order article via Infotrieve]
148. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1–12.[CrossRef][Medline] [Order article via Infotrieve]
149. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557–560.
150. Henry DA, Moxey AJ, Carless PA, O’Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Data Syst Rev. 2001: CD001886.
151. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O’Connor GT, Dacey LJ. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation. 1999; 99: 81–89.
152. Diprose P, Herbertson MJ, O’Shaughnessy D, Deakin CD, Gill RS. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. Br J Anaesth. 2005; 94: 271–278.
153. Ray MJ, O’Brien MF. Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost. Ann Thorac Surg. 2001; 71: 838–843.
154. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004; 128: 442–448.
155. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion. 2006; 46: 327–338.[CrossRef][Medline] [Order article via Infotrieve]
156. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004; 15: 1597–1605.
157. US Food and Drug Administration Center for Drug Evaluation and Research. Aprotinin injection (marketed as Trasylol) information. Available at: http://www.fda.gov/cder/drug/infopage/aprotinin/default.htm. Accessed December 15, 2006.
158. Lass M, Simic O, Ostermeyer J. Re-graft patency and clinical efficacy of aprotinin in elective bypass surgery. Cardiovasc Surg. 1997; 5: 604–607.[CrossRef][Medline] [Order article via Infotrieve]
159. Lass M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A. Aprotinin in elective primary bypass surgery: graft patency and clinical efficacy. Eur J Cardiothorac Surg. 1995; 9: 206–210.[Abstract]
160. Lemmer JH Jr, Dilling EW, Morton JR, Rich JB, Robicsek F, Bricker DL, Hantler CB, Copeland JG 3rd, Ochsner JL, Daily PO, Whitten CW, Noon GP, Maddi R. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg. 1996; 62: 1659–1667.
161. Rhydderch RD, Khan B, Saleh A. Single dose aprotinin in routine cardiac surgery. Middle East J Anesthesiol. 1993; 12: 287–297.[Medline] [Order article via Infotrieve]
|
Footnotes |
|---|
The online-only Data Supplement, consisting of a table and references, is available with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.106.671222/DC1.
This article has been cited by other articles:
 |
|
 |
|
  H. Takagi, H. Manabe, N. Kawai, S.-n. Goto, and T. Umemoto Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials Interactive CardioVascular and Thoracic Surgery, July 1, 2009; 9(1): 98 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Greilich, M. E. Jessen, N. Satyanarayana, C. W. Whitten, G. A. Nuttall, J. M. Beckham, M. H. Wall, and J. F. Butterworth The Effect of Epsilon-Aminocaproic Acid and Aprotinin on Fibrinolysis and Blood Loss in Patients Undergoing Primary, Isolated Coronary Artery Bypass Surgery: A Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial Anesth. Analg., July 1, 2009; 109(1): 15 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Manrique, E. H. Jooste, B. A. Kuch, S. E. Lichtenstein, V. Morell, R. Munoz, D. Ellis, and P. J. Davis The Association of Renal Dysfunction and the Use of Aprotinin in Patients Undergoing Congenital Cardiac Surgery Requiring Cardiopulmonary Bypass Anesth. Analg., July 1, 2009; 109(1): 45 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Karkouti, D. N. Wijeysundera, T. M. Yau, J. L. Callum, D. C. Cheng, M. Crowther, J.-Y. Dupuis, S. E. Fremes, B. Kent, C. Laflamme, et al. Acute Kidney Injury After Cardiac Surgery: Focus on Modifiable Risk Factors Circulation, February 3, 2009; 119(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. McIlroy, P. S. Myles, L. E. Phillips, and J. A. Smith Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis Br. J. Anaesth., February 1, 2009; 102(2): 168 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Henry MBChB, P. Carless BHSc MMedS, D. Fergusson PhD MHA, and A. Laupacis MD MSc The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis Can. Med. Assoc. J., January 20, 2009; 180(2): 183 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Breuer, K. Martin, M. Wilhelm, G. Wiesner, C. Schreiber, J. Hess, R. Lange, and P. Tassani The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery Eur. J. Cardiothorac. Surg., January 1, 2009; 35(1): 167 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ho, P. N. Peterson, and F. A. Masoudi Evaluating the Evidence: Is There a Rigid Hierarchy? Circulation, October 14, 2008; 118(16): 1675 - 1684. [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Olenchock Jr, P. H.U. Lee, T. Yehoshua, S. A. Murphy, J. Symes, and G. Tolis Jr Impact of Aprotinin on Adverse Clinical Outcomes and Mortality up to 12 Years in a Registry of 3,337 Patients Ann. Thorac. Surg., August 1, 2008; 86(2): 560 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lindvall, U. Sartipy, T. Ivert, and J. van der Linden Aprotinin is Not Associated With Postoperative Renal Impairment After Primary Coronary Surgery Ann. Thorac. Surg., July 1, 2008; 86(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Karkouti and W. S. Beattie Letter by Karkouti and Beattie Regarding Article "Aprotinin Does Not Increase the Risk of Renal Failure in Cardiac Surgery Patients" Circulation, June 3, 2008; 117(22): e472 - e472. [Full Text] [PDF]
|
|
|
|
|
|
J. G.T. Augoustides Letter by Augoustides Regarding Article "Aprotinin Does Not Increase the Risk of Renal Failure in Cardiac Surgery Patients" Circulation, June 3, 2008; 117(22): e474 - e474. [Full Text] [PDF]
|
|
|
|
|
|
A. Levrat, A. Gros, L. Rugeri, K. Inaba, B. Floccard, C. Negrier, and J.-S. David Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients Br. J. Anaesth., June 1, 2008; 100(6): 792 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Fergusson, P. C. Hebert, C. D. Mazer, S. Fremes, C. MacAdams, J. M. Murkin, K. Teoh, P. C. Duke, R. Arellano, M. A. Blajchman, et al. A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery N. Engl. J. Med., May 29, 2008; 358(22): 2319 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Bittner, J. Lemke, M. Lange, A. Rastan, and F. W. Mohr The Impact of Aprotinin on Blood Loss and Blood Transfusion in Off-Pump Coronary Artery Bypass Grafting Ann. Thorac. Surg., May 1, 2008; 85(5): 1662 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Jones The Year in Cardiovascular Surgery J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1707 - 1718. [Full Text] [PDF]
|
|
|
|
|
|
L. H. Edmunds Jr and R. W. Colman Bleeding That Won't Stop Ann. Thorac. Surg., April 1, 2008; 85(4): 1153 - 1154. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pagano, N. J. Howell, N. Freemantle, D. Cunningham, R. S. Bonser, T. R. Graham, J. Mascaro, S. J. Rooney, I. C. Wilson, R. Cramb, et al. Bleeding in cardiac surgery: The use of aprotinin does not affect survival J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schneeweiss, J. D. Seeger, J. Landon, and A. M. Walker Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death N. Engl. J. Med., February 21, 2008; 358(8): 771 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Shaw, M. Stafford-Smith, W. D. White, B. Phillips-Bute, M. Swaminathan, C. Milano, I. J. Welsby, S. Aronson, J. P. Mathew, E. D. Peterson, et al. The Effect of Aprotinin on Outcome after Coronary-Artery Bypass Grafting N. Engl. J. Med., February 21, 2008; 358(8): 784 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.T. Augoustides Prolonged mechanical ventilation after cardiovascular surgery. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 463 - 464. [Full Text] [PDF]
|
|
|
|
|
|
C. R. Bridges Valid Comparisons of Antifibrinolytic Agents Used in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2790 - 2792. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||